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Background: Authors from the Canadian Agency for Drugs and Technologies in Health (CADTH) presented an
analysis of submissions to the Common Drug Review (CDR) between 2004 and February 3, 2016 for drugs for rare
disorders (disorders with a prevalence of <50 per 100,000).
Objective: The aim of this analysis was to examine the same CDR submissions to evaluate whether the negative
reimbursement recommendation rate, clinical evidence of efficacy and statements concerning the drug’s cost in
the CDR reports varied with the prevalence of the disorder treated by the drug grouped into three decreasing
categories: <50 to >10, ≤10 to >1, and ≤1 per 100,000.
Results: As the prevalence of the treated disorder decreased, the median daily cost of the drug, the negative
recommendation rate and the proportion of submissions with statements in the CDR reports highlighting the cost
of the drug increased, while the proportion of submissions with acceptable evidence of clinical efficacy decreased.
Moreover, although the CADTH authors reported that only two submissions received a negative recommendation
due to a “lack of cost-effectiveness/high cost,” high cost was mentioned in the CDR reports of 15 drugs with
negative recommendations, all for disorders with a prevalence of ≤10 per 100,000.
Conclusions: The aggregated analysis of CDR submissions for drugs for disorders with wide ranging prevalence
rates concealed information of concern to patients. The negative reimbursement recommendation rate and the
significance of cost in the CDR assessments increased as the prevalence of the treated disorder decreased. Since
2012, the manner in which high cost drugs for rare disorders have been dealt with by the CDR has changed.
Cost has ceased to be a factor in negative recommendations but is included in criteria accompanying positive
recommendations. This trend is associated with the integration of the CDR process with the system for price
negotiation between public drug plans and pharmaceutical companies.
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In Canada, the health technology assessment of non-
oncology drugs for consideration for reimbursement in
public drug plans is performed by the Canadian Agency
for Drugs and Technologies in Health (CADTH)
through its Common Drug Review (CDR) process. The
CDR’s approach to evaluating the value of drugs for rare
disorders (DRDs) has long been criticized [1–5] as beingCorrespondence: EastlakeRG@gmail.com
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ommendations that have led to inequitable access to
DRDs across Canada. Proposals for a separate, more
broad-based process for these drugs have been rejected
by CADTH [6].
Employees of CADTH recently reported on an analysis
of submissions for DRDs to the CDR between 2004 and
February 3, 2016 [7]. They used Health Canada’s defin-
ition of a rare disorder, i.e. a prevalence of <50 per
100,000 individuals [8]. The CADTH authors found that
more than half of the submissions received a positive re-
imbursement recommendation and that the main reasonle is distributed under the terms of the Creative Commons Attribution 4.0
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efficacy [7]. They also reported that a “lack of cost-
effectiveness/high cost” was the reason for a negative rec-
ommendation in only two submissions and that “high cost
was not a reason for a negative reimbursement recom-
mendation in any recommendation after October 2012.”
The objective of the present analysis was to exam-
ine the same CDR submissions to assess whether the
negative recommendation rate, level of clinical evi-
dence and statements in the CDR reports regarding
the drug’s cost varied with the prevalence of the dis-
order treated by the drug.
Methods
Eight of the 63 CDR submissions for DRDs in the
CADTH article did not include a reimbursement recom-
mendation; four were ongoing, one was withdrawn and
three were Requests for Advice. The remaining 55 sub-
missions were grouped by the prevalence of the disorder
treated by the drug into three decreasing categories: <50
to >10, ≤10 to >1, and ≤1 per 100,000.
Within each prevalence category, the following were
evaluated from the CDR reports:
 Time required for the CDR assessment of each drug,
defined as the number of days between the
submission date and the date of the final
recommendation.
 Daily drug cost estimated from prices available in
the CDR recommendation reports for DRDs taken
daily.
 Number of randomized clinical trials (RCTs) and
number of patients in the RCTs.
 Negative reimbursement recommendation rate.
 Number of CDR assessments in which (a)
statistically significant evidence of clinical efficacy
was demonstrated in a clinically relevant outcome
in the RCT(s) included in the submission that the
review committee found to be acceptable, (b)
concern was expressed about the reliability of the
cost-effectiveness analysis, (c) attention was drawn
to the high cost of the drug or the need for a price
reduction in the recommendation statement, and (d)
the drug’s high cost was not mentioned in the rec-
ommendation statement but was noted elsewhere.
The CDR reports were generally transparent about the
acceptability of the quality of the evidence regarding
clinical efficacy and concerns about the reliability of the
cost-effectiveness analysis. Attention being drawn to the
high cost of a drug was derived from statements such as
the cost “is exceptionally high” or treatment options
exist that are “less costly,” while the need for a price re-
duction was identified from statements such as this drug“would not be considered cost-effective without a sub-
stantial reduction in the submitted price.”
The Kruskal-Wallis test and the chi-squared test for
trend were used to analyze numeric and ordinal vari-
ables, respectively.
Results
The prevalence rates of the disorders for which the drugs
were indicated ranged widely from 0.2 to 44.7 per
100,000. None of the drugs for disorders with a prevalence
of >10 per 100,000 were indicated for genetic disorders.
However, nine (39.1%) and 12 (92.3%) of the drugs for dis-
orders with prevalence rates of ≤10 to >1 and ≤1 per
100,000, respectively, were indicated for genetic disorders
(a statistically significant trend, p = 0.002).
As the prevalence of the treated disorder decreased, the
median daily cost, the negative reimbursement recom-
mendation rate, the proportion of assessments in which
concern was expressed about the reliability of the cost-
effectiveness analysis, and the proportion in which atten-
tion was drawn to the high cost or the need for a price
reduction significantly increased (Table 1). The median
number of patients in the RCTs and the proportion of
assessments with acceptable evidence of clinical efficacy
decreased significantly as the prevalence decreased.
High cost was not a factor in submissions with a nega-
tive recommendation for any drug designed to treat a
disorder with a prevalence of >10 per 100,000. However,
attention was drawn to the high cost or the need for a
price reduction mentioned in the CDR recommendation
statement in 70.0% and 80.0% of drugs for disorders with
prevalence rates of ≤10 to >1 and ≤1 per 100,000,
respectively, that received a negative reimbursement
recommendation (Table 2).
As the CADTH authors noted, high cost was not a
reason for any negative reimbursement recommendation
from 2012 onward, whereas prior to 2012, high cost was
mentioned in 85% of the negative recommendation
statements for drugs for disorders with a prevalence of
≤10 per 100,000 (Table 3). Conversely, the proportion of
positive reimbursement recommendation statements for
drugs for disorders with a prevalence of ≤10 per 100,000
that included comments about their high cost increased
from 14.3% in 2004–2011 to 100% from 2012 onward.
Discussion
Health Canada’s definition of a rare disorder as one with a
prevalence of <50 per 100,000 [8] is broad, resulting in the
CADTH authors including drugs for disorders with preva-
lence rates ranging from 0.2 to 44.7 per 100,000, i.e. the
potential numbers of Canadian patients varied from 70 to
15,645. The use of this definition allowed the CADTH
authors to report a negative reimbursement recommenda-
tion rate for DRDs of 45%, which is consistent with the
Table 1 CDR assessment results for 55 submissions by prevalence of treated disorder
Prevalence of treated disorder (per 100,000) p-value
<50 to >10 ≤10 to >1 ≤1
n = 19 n = 23 n = 13
Median assessment time (range) 203 (164–251) 195 (126–392) 232 (153–439) 0.409
Median daily cost (range)a $55 ($13–$252) $186 ($26–$1800) $796 ($181–$1460) 0.0001
Median number of RCTs (range) 2 (1–6) 2 (1–4) 1 (0–4) 0.100
Median number of patients in RCTs (range) 120 (15–555) 118 (12–742) 58 (11–177) 0.020
No. with a negative recommendation 5 (26.3%) 10 (43.5%) 10 (76.9%) 0.006
No. with acceptable clinical efficacy evidence 14 (73.7%) 11 (47.8%) 2 (15.4%) 0.001
No. with concern about cost-effectiveness analysis 9 (47.4%) 18 (78.3%) 12 (92.3%) 0.004
No. with high cost or need for price reduction stated in the recommendation 3 (15.8%) 10 (43.5%) 6 (46.2%) 0.057
No. with high cost noted elsewhere in the report 0 (0.0%) 1 (4.3%) 2 (15.4%) 0.067
No. with high cost or need for price reduction noted anywhere in the report 3 (15.8%) 11 (47.8%) 8 (61.5%) 0.007
CDR Common Drug Review, RCT Randomized clinical trial
aCalculated for drugs used daily from prices available in the CDR reports
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ever, the aggregation of drugs for disorders with such
wide prevalence rates concealed important details such
as a negative recommendation rate for drugs for ultra-
rare disorders, i.e. those with a prevalence of ≤1 per
100,000, of 77%.
Almost all the drugs for ultra-rare disorders were
indicated for genetic disorders and had only a median
number of 58 patients in the RCTs included the CDR
submissions. Only 15.4% of the submissions for these
drugs had acceptable evidence of clinical efficacy. One of
the reasons for the high negative recommendation rate
for drugs for rarer disorders is the CDR’s continuing re-
quirement for RCTs with hard outcomes and adequate
numbers to provide statistically convincing results to
supply evidence of clinical efficacy. RCTs of drugs for
such disorders with sufficient statistical power over a
reasonable period of time are difficult, if not impos-
sible, to perform due to the small numbers of poten-
tial participants. Moreover, when a drug becomes
available for a rare disorder that severely impacts the
quality or extent of life for which no effective treat-
ment currently exists (most of the drugs for genetic
disorders were unique innovative therapies), ethical
considerations may prevent a RCT.Table 2 High cost noted in 25 CDR reports with a negative reimbur
No. with high cost or need for price reduction stated in the recommendatio
No. with high cost noted elsewhere in the report
No. with high cost or need for price reduction noted anywhere in the report
CDR Common Drug ReviewThe CADTH authors categorized the reason for a
negative reimbursement recommendation as insufficient
or lack of evidence of clinical efficacy, lack of cost-
effectiveness/high cost, or multiple issues [7]; a “lack of
cost-effectiveness/high cost” was the reason in only two
submissions. In the present analysis, the drug’s high cost
was mentioned in the CDR recommendation statements
or remarked upon in the text of the reports of 15 DRDs,
all for disorders with a prevalence of ≤10 per 100,000.
High cost, therefore, appears to have played a greater
role in the probability of a negative CDR recommenda-
tion than the CADTH authors’ categorization suggests.
In addition, a change has occurred in how high cost
DRDs are dealt with by the CDR. Before 2012, high cost
was a factor in 85% of the negative reimbursement rec-
ommendations for drugs for disorders with a prevalence
of ≤10 per 100,000. However, since 2012, none of the
drugs in this prevalence category that received a negative
recommendation had its cost noted in the recommenda-
tion statement, while 100% of drugs for disorders in this
category with a positive reimbursement recommenda-
tion have included criteria advocating a price reduction
or drawing attention to less expensive alternative drugs.
This trend has continued in five recent CDR reports for
drugs for disorders with a prevalence of ≤10 per 100,000sement recommendation
Prevalence of treated disorder (per 100,000) p-value
<50 to >10 ≤10 to >1 ≤1
n = 5 n = 10 n = 10
n 0 (0.0%) 6 (60.0%) 5 (50.0%) 0.132
0 (0.0%) 1 (10.0%) 3 (30.0%) 0.109
0 (0.0%) 7 (70.0%) 8 (80.0%) 0.006
Table 3 High cost noted in the CDR reimbursement recommendation statements for drugs for disorders with a prevalence of ≤10
per 100,000, by time period
Time period Recommendation Prevalence of treated disorder (per 100,000) Total
≤10 to >1 ≤1
Before 2012 Positive 1 (20.0%) 0 (0.0%) 1 (14.3%)
Negative 6 (85.7%) 5 (83.3%) 11 (84.6%)
2012 onward Positive 8 (100.0%) 1 (100.0%) 9 (100.0%)
Negative 0 (0.0%) 0 (0.0%) 0 (0.0%)
CDR Common Drug Review
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substantial price reduction; in one case, the CDR recom-
mended an 80% price reduction.
This change in CDR recommendations is part of the
process of integrating CADTH with the pan-Canadian
Pharmaceutical Alliance (pCPA) which “conducts joint
provincial/territorial negotiations for brand name drugs
in Canada to achieve greater value for publicly funded
drug programs and patients” [10, 11]. Representatives of
the pCPA now attend CDR submission review meetings
where pricing and other implementation issues that im-
pact the pCPA and public drug plans are considered
when recommendations are made [12]. The results of
the present analysis of CDR recommendations for DRDs
indicate that an objective of the CADTH-pCPA integra-
tion is to ensure that a negative reimbursement recom-
mendation results in no pCPA negotiation, while a
positive recommendation sets up factors for inclusion in
the price negotiation―a scenario that is apparent in
several recent reimbursement recommendations for
drugs for common disorders.
The present analysis only included 55 CDR submis-
sions that had a reimbursement recommendation, unlike
the CADTH authors who also included the eight sub-
missions without a recommendation in some of their
analyses. The CADTH authors reported 26 submissions
as having a negative recommendation, whereas 25 were
identified in this analysis. Qualitative variables used in
both analyses could be considered open to interpret-
ation. However, the number of submissions with a nega-
tive reimbursement recommendation resulting from a
lack of acceptable clinical efficacy evidence was similar
in the CADTH analysis and the present one. A further
limitation is that only small numbers were available in
some comparisons, although they were usually sufficient
to be able to identify statistically significant differences.
Conclusions
The earlier aggregated analysis of submissions to the CDR
for drugs for disorders with wide ranging prevalence rates
concealed information of concern to patients, such as the
high negative reimbursement recommendation rate fordrugs for ultra-rare disorders. Since 2012, the manner in
which high cost drugs for disorders with a prevalence of
≤10 in 100,000 are dealt with by the CDR has changed to
harmonize its process with the system for price negoti-
ation between public drug plans and pharmaceutical
companies.
Canada remains one of few industrialized countries
without an orphan drug policy to provide manufacturers
with incentives to develop and market DRDs [13].
Health Canada announced an Orphan Drug Regulatory
Framework in 2012 [14, 15] that is designed to increase
research and innovation and facilitate patient access to
DRDs, but it has yet to be approved. With many new
expensive DRDs in development, a pressing need exists
for Canadian federal and provincial governments to
implement the Framework and to develop coherent
nationwide policies to ensure that DRDs are reviewed by
CADTH and funded by public drug plans in a timely
and fair manner so that they are made available to all
Canadians who need them.
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